Evidence map›Paper›PMID 32747382›Full record

ArticleBMJ open diabetes research & care2020

Adipokines in early and mid-pregnancy and subsequent risk of gestational diabetes: a longitudinal study in a multiracial cohort.

Ellen C Francis, Mengying Li, Stefanie N Hinkle, Yaqi Cao, Jinbo Chen, Jing Wu, Yeyi Zhu, Haiming Cao, Karen Kemper, Lior Rennert and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open diabetes research & care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Metabolic Roles of Fatty Acid Binding Protein 4 (FABP4) in Fetal and Maternal Health and Maintenance of Pregnancy in Women with Obesity: A Review.Medical science monitor : international medical journal of experimental and clinical research · 2025
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. First Trimester Placental Biomarkers for Pregnancy Outcomes.International journal of molecular sciences · 2024
    Review
  16. Article
  17. Review
  18. Molecular pathways in placental-fetal development and disruption.Molecular and cellular endocrinology · 2024
    Review
  19. Risk Estimation of Gestational Diabetes Mellitus in the First Trimester.The Journal of clinical endocrinology and metabolism · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Ellen C FrancisColorado School of Public Health, University of Colorado Denver - Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0001-8618-045X
Mengying LiDivision of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA.ORCID 0000-0002-3713-1683
Stefanie N HinkleDivision of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA.
Yaqi CaoBiostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Jinbo ChenBiostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Jing WuGlotech, Rockville, Maryland, USA.
Yeyi ZhuDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Haiming CaoCardiovascular Branch, National Heart Lung and Blood Institute, Bethesda, Maryland, USA.
Karen KemperDepartment of Public Health Sciences, Clemson University College of Behavioral, Social and Health Sciences, Clemson, South Carolina, USA.
Lior RennertDepartment of Public Health Sciences, Clemson University College of Behavioral, Social and Health Sciences, Clemson, South Carolina, USA.
Joel WilliamsDepartment of Public Health Sciences, Clemson University College of Behavioral, Social and Health Sciences, Clemson, South Carolina, USA.
Michael Y TsaiLaboratory Medicine and Pathology, University of Minnesota System, Minneapolis, Minnesota, USA.
Liwei ChenEpidemiology, University of California Los Angeles Jonathan and Karin Fielding School of Public Health, Los Angeles, California, USA.
Cuilin ZhangDivision of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, USA zhangcu@mail.nih.gov.
Clemson University · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USCancer Research And Biostatistics · USColorado School of Public Health · USGlotech (United States) · USKaiser Permanente · USNational Heart Lung and Blood Institute · USUniversity of California, Los Angeles · USUniversity of Minnesota System · US

Funding

Molecular Basis of Obesity and Obesity-induced Metabolic DiseasesZIAHL006103 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CAO, HAIMING · 2011 to 2025
$19.8M
Modeling Type II Diabetes and Lipodystrophy Using Patient-Specific iPS CellsZIAHL006159 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CAO, HAIMING · 2012 to 2025
$14.2M
The National Standard for Normal Fetal GrowthZIAHD008852 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI GRANTZ, KATHERINE · 2009 to 2025
$5.6M
Pathogenesis of Gestational DiabetesZIAHD008887 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI YEUNG, EDWINA · 2009 to 2022
$2.3M
Fetal Programming of Growth and Obesity: A Metabolomics ApproachK01DK120807 · NIDDK · KAISER FOUNDATION RESEARCH INSTITUTE · PI ZHU, YEYI · 2019 to 2022
$699k
NICHD NIH HHS HHSN275200800001CNICHD NIH HHS HHSN275200800002CNICHD NIH HHS HHSN275200800002INICHD NIH HHS HHSN275200800003CNICHD NIH HHS HHSN275200800003INICHD NIH HHS HHSN275200800012CNICHD NIH HHS HHSN275200800013CNICHD NIH HHS HHSN275200800014CNICHD NIH HHS HHSN275200800028CNICHD NIH HHS HHSN275201000001GNICHD NIH HHS HHSN275201000001ZNICHD NIH HHS HHSN275201000009CNIDDK NIH HHS K01 DK120807
6 · The paper itself

Abstract

introductionSeveral adipokines are implicated in the pathophysiology of gestational diabetes mellitus (GDM), however, longitudinal data in early pregnancy on many adipokines are lacking. We prospectively investigated the association of a panel of adipokines in early and mid-pregnancy with GDM risk. RESEARCH DESIGN AND

methodsWithin the National Institute of Child Health and Human Development (NICHD) Fetal Growth Studies-Singletons cohort (n=2802), a panel of 10 adipokines (plasma fatty acid binding protein-4 (FABP4), chemerin, interleukin-6 (IL-6), leptin, soluble leptin receptor (sOB-R), adiponectin, omentin-1, vaspin, and retinol binding protein-4) were measured at gestational weeks (GWs) 10-14, 15-26, 23-31, and 33-39 among 107 GDM cases (ascertained on average at GW 27) and 214 non-GDM controls. Conditional logistic regression was used to estimate ORs of each adipokine and GDM, controlling for known GDM risk factors including pre-pregnancy body mass index.

resultsThroughout pregnancy changes in chemerin, sOB-R, adiponectin, and high-molecular-weight adiponectin (HMW-adiponectin) concentrations from 10-14 to 15-26 GWs were significantly different among GDM cases compared with non-GDM controls. In early and mid-pregnancy, FABP4, chemerin, IL-6 and leptin were positively associated with increased GDM risk. For instance, at 10-14 GWs, the OR comparing the highest versus lowest quartile (ORQ4-Q1) of FABP4 was 3.79 (95% CI 1.63 to 8.85). In contrast, in both early and mid-pregnancy adiponectin (eg, ORQ4-Q1 0.14 (0.05, 0.34) during 10-14 GWs) and sOB-R (ORQ4-Q1 0.23 (0.11, 0.50) during 10-14 GWs) were inversely related to GDM risk. At 10-14 GWs a model that included conventional GDM risk factors and FABP4, chemerin, sOB-R, and HMW-adiponectin improved the estimated prediction (area under the curve) from 0.71 (95% CI 0.66 to 0.77) to 0.77 (95% CI 0.72 to 0.82).

conclusionsA panel of understudied adipokines including FABP4, chemerin, and sOB-R may be implicated in the pathogenesis of GDM with significant associations detected approximately 10-18 weeks before typical GDM screening.

Indexed as

Diabetes, GestationalAdipokinesAdiponectinChemokinesChildFemaleHumansLeptinLongitudinal StudiesPregnancyAdipokinesAdiponectinChemokinesLeptinRARRES2 protein, humanadipokinescohortgestational diabetes mellitusprospective

Identifiers

PMID32747382
PMCPMC7398109
OpenAlexW3047009205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.